Public Equities Strategy

Our public equities strategy invests in IPOs, SPACs, PIPEs, and publicly traded securities of breakthrough biomedical technology companies.  

Our robust private equity business, anchored by our flagship venture strategy, generates proprietary deal flow and allocations in new issues; and our in-house research team works seamlessly with our unparalleled team of world-renowned scientists and entrepreneurs to identify small cap companies that can outperform.